全文获取类型
收费全文 | 42705篇 |
免费 | 1521篇 |
国内免费 | 139篇 |
专业分类
耳鼻咽喉 | 135篇 |
儿科学 | 1102篇 |
妇产科学 | 611篇 |
基础医学 | 2483篇 |
口腔科学 | 673篇 |
临床医学 | 5757篇 |
内科学 | 5358篇 |
皮肤病学 | 377篇 |
神经病学 | 1520篇 |
特种医学 | 465篇 |
外科学 | 2165篇 |
综合类 | 4339篇 |
一般理论 | 4篇 |
预防医学 | 15773篇 |
眼科学 | 205篇 |
药学 | 2124篇 |
20篇 | |
中国医学 | 542篇 |
肿瘤学 | 712篇 |
出版年
2023年 | 800篇 |
2022年 | 1411篇 |
2021年 | 1936篇 |
2020年 | 2098篇 |
2019年 | 3218篇 |
2018年 | 2315篇 |
2017年 | 1578篇 |
2016年 | 950篇 |
2015年 | 1200篇 |
2014年 | 3104篇 |
2013年 | 2914篇 |
2012年 | 2672篇 |
2011年 | 2941篇 |
2010年 | 2264篇 |
2009年 | 2080篇 |
2008年 | 1994篇 |
2007年 | 1879篇 |
2006年 | 1424篇 |
2005年 | 914篇 |
2004年 | 748篇 |
2003年 | 577篇 |
2002年 | 477篇 |
2001年 | 410篇 |
2000年 | 348篇 |
1999年 | 289篇 |
1998年 | 232篇 |
1997年 | 178篇 |
1996年 | 94篇 |
1995年 | 105篇 |
1994年 | 82篇 |
1993年 | 83篇 |
1992年 | 72篇 |
1991年 | 45篇 |
1990年 | 31篇 |
1989年 | 27篇 |
1988年 | 23篇 |
1987年 | 26篇 |
1985年 | 253篇 |
1984年 | 366篇 |
1983年 | 301篇 |
1982年 | 308篇 |
1981年 | 297篇 |
1980年 | 242篇 |
1979年 | 230篇 |
1978年 | 204篇 |
1977年 | 150篇 |
1976年 | 136篇 |
1975年 | 119篇 |
1974年 | 100篇 |
1973年 | 77篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Bulletin du cancer》2023,110(2):145-150
2.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
3.
Hunter Hahn PhD Kelly H. Burkitt PhD Michael R. Kauth PhD Jillian C. Shipherd PhD John R. Blosnich PhD MPH 《Health services research》2023,58(2):392-401
Objective
This study examined the primary source of health care between veterans with lesbian, gay, bisexual, queer and similar identities (LGBTQ+) and non-LGBTQ+ veterans.Data Sources and Study Setting
Veterans (N = 20,497) from 17 states who completed the CDC's Behavioral Risk Factor Surveillance System from 2016 to 2020, including the Sexual Orientation and Gender Identity and Health Care Access modules.Study Design
We used survey-weighted multiple logistic regression to estimate average marginal effects of the prevalence of utilization of Veteran's Health Administration (VHA)/military health care reported between LGBTQ+ and non-LGBTQ+ veterans. Prevalence estimates were adjusted for age group, sex, race and ethnicity, marital status, educational attainment, employment status, survey year, and US state.Data Collection Methods
Study data were gathered via computer-assisted telephone interviews with probability-based samples of adults aged 18 and over. Data are publicly available.Principal Findings
Overall, there was not a statistically significant difference in estimated adjusted prevalence of primary use of VHA/military health care between LGBTQ+ and non-LGBTQ+ veterans (20% vs. 23%, respectively, p = 0.13). When examined by age group, LGBTQ+ veterans aged 34 and younger were significantly less likely to report primary use of VHA/military health care compared to non-LGBTQ+ veterans (25% vs. 44%, respectively; p = 0.009). Similarly, in sex-stratified analyses, fewer female LGBTQ+ veterans than female non-LGBTQ+ veterans reported VHA/military health care as their primary source of care (13% vs. 29%, respectively, p = 0.003). Implications and limitations to these findings are discussed.Conclusions
Female and younger LGBTQ+ veterans appear far less likely to use VHA/military for health care compared to their cisgender, heterosexual peers; however, because of small sample sizes, estimates may be imprecise. Future research should corroborate these findings and identify potential reasons for these disparities. 相似文献4.
Brede H. Eschliman MPH Hongmai H. Pham MD PhD Amol S. Navathe MD PhD Karen M. Dale BSN MSN Julian Harris MD MBA 《Health services research》2023,58(Z3):311-317
Objective
The aim was to identify healthcare payment and financing reforms to promote health equity and ways that the Agency for Healthcare Research and Quality (AHRQ) may promote those reforms.Data Sources and Study Setting
AHRQ convened a payment and financing workgroup–the authors of this paper–as part of its Health Equity Summit held in July 2022. This workgroup drew from its collective experience with healthcare payment and financing reform, as well as feedback from participants in a session at the Health Equity Summit, to identify the evidence base and promising paths for reforms to promote health equity.Study Design
The payment and financing workgroup developed an outline of reforms to promote health equity, presented the outline to participants in the payment and financing session of the July 2022 AHRQ Health Equity Summit, and integrated feedback from the participants.Data Collection/Extraction Methods
This paper did not require novel data collection; the authors collected the data from the existing evidence base.Principal Findings
The paper outlines root causes of health inequity and corresponding potential reforms in five domains: (1) the differential distribution of resources between healthcare providers serving different communities, (2) scarcity of financing for populations most in need, (3) lack of integration/accountability, (4) patient cost barriers to care, and (5) bias in provider behavior and diagnostic tools.Conclusions
Additional research is necessary to determine whether the proposed reforms are effective in promoting health equity. 相似文献5.
This paper tests for the presence of job lock and “health insurance plan lock” stemming from the health shock of a child family member. Using the onset of an acute, unanticipated health shock, I estimate a 7–14 percent decreased likelihood of all family members leaving their current health insurance network and health plan within one year of the emergency. This corresponds to a reduced one-year job mobility rate of approximately 13 percent for the health plan’s primary policyholder. Furthermore, the non-portability of health insurance products may contribute to the observed job and health plan lock. 相似文献
6.
Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to inform decisions about access and reimbursement. We study how CE thresholds imposed by a health plan for granting reimbursement affect drug producers’ pricing incentives and patients’ access to new drugs. Analysing a sequential pricing game between an incumbent drug producer and a potential entrant with a new drug, we show that CE thresholds may have adverse effects for payers and patients. A stricter CE threshold may induce the incumbent to switch pricing strategy from entry accommodation to entry deterrence, limiting patients’ access to the new drug. Otherwise, irrespective of whether entry is deterred or accommodated, a stricter CE threshold is never pro-competitive and may in fact facilitate a collusive outcome with higher prices of both drugs. Compared to a laissez-faire policy, the use of CE thresholds when an incumbent monopolist is challenged by therapeutic substitutes can only increase the surplus of a health plan if it leads to entry deterrence. In this case the price reduction by the incumbent necessary to deter entry outweighs the health loss to patients who do not get access to the new drug. 相似文献
7.
《Enfermedades infecciosas y microbiología clínica》2022,40(6):326-329
IntroductionAs of 30 April 2020, 203.715 SARS-CoV-2 infections had been reported in Spain, 54.486 in Madrid, 21.4% were health care workers. Our objective is to determine seroprevalence of COVID-19 among workers in a monographic pediatric hospital.MethodsBetween April13th and 30th, 1.523 health workers were recruited to be tested for SARS-CoV-2 serology screening (All Test®) and they answered a questionnaire with demographic, epidemiological and clinical information and previous exposure to COVID-19.FindingsOne thousand two hundred ninety two (84.8%) were tested. Positive serology (IgM and/or IgG) to SARS-CoV-2 was found in 17.2% (222/1.292), in 15.5% (201/1.292) if only IgG was considered. Median age was 44±13 years, 73% were female. The 33.8% (75/222) were asymptomatic. Eighty one had a previous positive rRT-PCR. The 14% (32/222) referred a family contact.ConclusionSerology prevalence for SARS-CoV-2 in workers of a pediatric hospital was higher than in general population. Many of them had an unnoticed infection. 相似文献
8.
9.
10.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(1):151-159
Background & aimsTo determine the trends of self-reported non-adherence rates among adults taking Type 2 medicines (T2D) medicines between 2017 and 2019 and to identify the patterns for the frequently reported reasons for non-adherence in the United States.Methods & resultsData from the National Health and Wellness Survey, a self-administered, internet-based cross-sectional survey of US adults from 2017 to 2019 was used. Non-adherence was measured using the self-reported Medication Adherence Reasons Scale (MAR-Scale). Frequencies were used to identify the reasons for non-adherence for insulin and non-insulin therapies for T2D.Data were obtained from 2983 respondents in 2017, 5416 in 2018, and 5268 in 2019. Based on the MAR-Scale, the self-reported medication non-adherence rate was 25% in 2017, 21% in 2018, and 27% in 2019. The most common reason for non-adherence across all the three years was simple forgetfulness, yet patients reported the lowest mean number of days missing medication for that reason. Though less frequently reported, non-adherence lasted longer when patient did not know how to take their medicines, cost was a reason, or had concerns about the long term effects of the medicines.ConclusionsWith no significant improvement in adherence with T2D medicines over time, regardless of better awareness and extensive diabetes education, focus should be on individualized non-adherence reasons-based interventions. 相似文献